Stock HEMISPHERX BIOPHARMA, INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Analyst Reco. Hemispherx BioPharma, Inc Nyse

Equities

US42366C1036

End-of-day quote Nyse
Other stock markets
- USD - Intraday chart for Hemispherx BioPharma, Inc
Apr. 10 AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer CI
Apr. 02 Transcript : AIM ImmunoTech Inc., Q4 2023 Earnings Call, Apr 02, 2024

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Maxim Group Adjusts AIM ImmunoTech Price Target to $3 From $5, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AIM Stock
  4. Stock
  5. News Hemispherx BioPharma, Inc
  6. Analyst Reco.